Research advances on second primary malignancies of oral cavity following radiotherapy for nasopharyngeal carcinoma

Abstract

Abstract: Radiotherapy is the primary treatment modality for nasopharyngeal carcinoma（NPC） which can effectively control the disease. Oral cavity, anatomically near nasopharyngeal region is the main area for the occurrence of complication of radiotherapy. Second primary malignancy （SPM） in oral cavity is an important factor interferencing NPC patients survival rate. The etiology of oral SPM is unclear and, the prognosis is poor. The research of it is still in exploration.

Key words: Nasopharyngeal neoplasms, Radiotherapy, Mouth, Second primary malignancies

ZHAO Nan, WU Tong, CHENG Bin. Research advances on second primary malignancies of oral cavity following radiotherapy for nasopharyngeal carcinoma[J]. Journal of International Oncology, 2016, 43(2): 145-.

References

［1］ Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012［J］. Int J Cancer, 2015, 136(5): E359386. DOI:10.1002/ijc.29210. ［2］ Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (20082030): a populationbased study［J］. Lancet Oncol, 2012, 13(8): 790801. DOI:10.1016/S14702045(12)702115. ［3］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI:10.3322/caac.20107. ［4］ Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China［J］. Chin J Cancer, 2011, 30(2): 114119. ［5］ Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial［J］. Lancet Oncol, 2012, 13(2): 163171. DOI:10.1016/S14702045(11)703205. ［6］ Macready N. Looking treatment complications in the mouth［J］. J Natl Cancer Inst, 2013, 105(2): 7677. DOI:10.1093/jnci/djs643. ［7］ Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a metaanalysis of the phase Ⅲ randomized trials［J］. BMC Cancer, 2010, 10(1): 558. DOI:10.1186/1471240710558. ［8］黄引芳, 傅深, 章青, 等. 白细胞介素11预防和治疗头颈部肿瘤放疗导致口腔黏膜反应的疗效观察［J］. 国际肿瘤学杂志, 2010, 37(9): 710712 ［9］ Xi M, Liu SL, Zhao L, et al. Prognostic factors and survival in patients with radiationrelated second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma［J］. PLoS One, 2013, 8(12): e84586. DOI:10.1371/journal.pone.0084586. ［10］ Song M, Zhuang SM, Chen SW, et al. Survival study and treatment strategy for second primary tumors in the oral cavity in patients with nasopharyngeal carcinoma after definitive radiation［J］. Head Neck, 2012, 34(11): 15511555. DOI:10.1002/hed.21959. ［11］ Kong L, Lu JJ, Hu C, et al. The risk of second primary tumors in patients with nasopharyngeal carcinoma after definitive radiotherapy［J］. Cancer, 2006, 107(6): 12871293. DOI:10.1002/cncr.22119. ［12］ Wang CC, Chen ML, Hsu KH, et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with EpsteinBarr virus［J］. Int J Cancer, 2000, 87(2): 228231. ［13］ Chan JY, Gooi Z, Mydlarz WK, et al. Risk of second primary malignancy after nasopharyngeal carcinoma in the United States: a populationbased study［J］. Head Neck, 2015, in press. DOI:10.1002/hed.24173. ［14］ Lin C, Lin SW, Weng SF, et al. Risk of second primary malignancies after nasopharyngeal carcinoma: a populationbased cohort study in Taiwan［J］. Head Neck, 2014, 36(2): 209214. DOI:10.1002/hed.23281. ［15］ Chen MC, Feng IJ, Lu CH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a populationbased study in Taiwan over a 25year period (19792003)［J］. Ann Oncol, 2008, 19(6): 11801186. DOI:10.1093/annonc/mdn003. ［16］ Sun C, Hu Z, Zhong Z, et al. Clinical and prognostic analysis of second primary squamous cell carcinoma of the tongue after radiotherapy for nasopharyngeal carcinoma［J］. Br J Oral Maxillofac Surg, 2014, 52(8): 715720. DOI:10.1016/j.bjoms.2014.06.015. ［17］ Teo PM, Chan AT, Leung SF, et al. Increased incidence of tongue cancer after primary radiotherapy for nasopharyngeal carcinomathe possibility of radiation carcinogenesis［J］. Eur J Cancer, 1999, 35(2): 219225. ［18］孙传政, 陈福进, 曾宗渊, 等. 第一原发性舌癌和鼻咽癌放疗后第二原发性舌癌的比较分析［J］. 中华肿瘤杂志, 2006, 28(12): 938941 ［19］ Cha C, Antonescu CR, Quan ML, et al. Longterm results with resection of radiationinduced soft tissue sarcomas［J］. Ann Surg, 2004, 239(6): 903909. ［20］ Robbins KT, Samant S, Vieira F, et al. Presurgical cytoreduction of oral cancer using intraarterial cisplatin and limited concomitant radiation therapy (NeoRADPLAT)［J］. Arch Otolaryngol Head Neck Surg, 2004, 130(1): 2832. DOI:10.1001/archotol.130.1.28. ［21］ Rennemo E, Ztterstrm U, Boysen M. Impact of second primary tumors on survival in head and neck cancer: an analysis of 2 063 cases［J］. Laryngoscope, 2008, 118(8): 13501356. DOI:10.1097/MLG.0b013e318172ef9a. ［22］叶玲, 刘晓清, 周琦超, 等. 个体化口腔支架在鼻咽癌患者调强放疗中应用的剂量分析［J］. 中山大学学报:医学科学版, 2014, 35(1): 7479 ［23］ Berrington De Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US Seer cancer registries［J］. Lancet Oncol, 2011, 12(4): 353360. DOI:10.1016/S14702045(11)700614. ［24］ Goggins WB, Yu IT, Tse LA, et al. Risk of second primary malignancies following nasopharyngeal carcinoma in Hong Kong［J］. Cancer Causes Control, 2010, 21(9): 14611466. DOI:10.1007/s105520109574x. ［25］ Scélo G, Boffetta P, Corbex M, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries［J］. Cancer Causes Control, 2007, 18(3): 269278. DOI:10.1007/s105520060101z. ［26］ Lv P, Wang Y, Ma J, et al. Inhibition of protein phosphatase 2A with a small molecule LB100 radiosensitizes nasopharyngeal carcinoma xenografts by inducing mitotic catastrophe and blocking DNA damage repair［J］. Oncotarget, 2014, 5(17): 75127524.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[4]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[5]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[6]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[7]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[8]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[9]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[10]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[11]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.
[12]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[13]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[14]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[15]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.